Dyax Corp. and CSIRO Form Joint Antibody Discovery Collaboration in Oncology
During the discovery phase of the collaboration, Dyax will utilize its proprietary antibody libraries to screen for clinical candidates, and CSIRO will provide reagents and in vitro assays, as well as certain in vivo and preclinical development work. Upon successful completion of the discovery work, CSIRO and Dyax will have the option to advance the antibody lead(s) into clinical development under the terms of a global co-development and commercialization agreement.
Other news from the department science
These products might interest you
Micro-Dx™ CE IVD by Molzym
Fully automated from sample to PCR analysis
Rapid identification of bacteria and fungi without time-consuming cultivation
DNA-free Taq Polymerases and Mastermixes by Molzym
DNA-free reagents for unrivalled sensitivity in molecular biology
Purity that makes the difference
Greener Alternative Products by Merck Life Science
Sustainable laboratory products for environmentally conscious research
Over 2,500 ecological alternatives to reduce your laboratory footprint
Recombumin® Elite by Sartorius
ICHQ7 cGMP-compliant albumin for biotechnological applications
Increase consistency and safety for gene therapies and vaccines
CellGenix® Growth Factors and Cytokines by Sartorius
Recombinant growth factors without animal products
Optimised cell culture for T cells and MSCs in gene therapy
DNA/RNA Shield™ SafeCollect Collection Kits by Zymo Research
Sample collection devices for simple & safe at-home testing
Best user experience for secure self-collection
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous